Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic

Introduction Childhood cancer is a leading cause of death. It is unclear whether the COVID-19 pandemic has impacted childhood cancer mortality. In this study, we aimed to establish all-cause mortality rates for childhood cancers during the COVID-19 pandemic and determine the factors associated with mortality. Methods Prospective cohort study in 109 institutions in 41 countries. Inclusion criteria: children <18 years who were newly diagnosed with or undergoing active treatment for acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, retinoblastoma, Wilms tumour, glioma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, medulloblastoma and neuroblastoma. Of 2327 cases, 2118 patients were included in the study. The primary outcome measure was all-cause mortality at 30 days, 90 days and 12 months. Results All-cause mortality was 3.4% (n=71/2084) at 30-day follow-up, 5.7% (n=113/1969) at 90-day follow-up and 13.0% (n=206/1581) at 12-month follow-up. The median time from diagnosis to multidisciplinary team (MDT) plan was longest in low-income countries (7 days, IQR 3-11). Multivariable analysis revealed several factors associated with 12-month mortality, including low-income (OR 6.99 (95% CI 2.49 to 19.68); p<0.001), lower middle income (OR 3.32 (95% CI 1.96 to 5.61); p<0.001) and upper middle income (OR 3.49 (95% CI 2.02 to 6.03); p<0.001) country status and chemotherapy (OR 0.55 (95% CI 0.36 to 0.86); p=0.008) and immunotherapy (OR 0.27 (95% CI 0.08 to 0.91); p=0.035) within 30 days from MDT plan. Multivariable analysis revealed laboratory-confirmed SARS-CoV-2 infection (OR 5.33 (95% CI 1.19 to 23.84); p=0.029) was associated with 30-day mortality. Conclusions Children with cancer are more likely to die within 30 days if infected with SARS-CoV-2. However, timely treatment reduced odds of death. This report provides crucial information to balance the benefits of providing anticancer therapy against the risks of SARS-CoV-2 infection in children with cancer

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Background: Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. // Methods: We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung's disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. // Findings: We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung's disease) from 264 hospitals (89 in high-income countries, 166 in middle-income countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in low-income countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. // Interpretation: Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between low-income, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

Cooperation And Innovation: Linking Theory And Practice [cooperação E Inovação: Relacionando A Teoria E A Prática]

Based on research on business networks and competitive strategy, this paper explores some dialogues and reflections among the concepts of business relationships, cooperation and innovation. Besides, the Business Cooperation Network has appeared as a dynamic configuration of resources and capabilities between firms. It is argued that cooperative relationships and trust are fundamental ways to compete in turbulent environments. The literature of networks, cooperation and innovation is then revisited and, throughout the paper, some practical examples are provided. Finally, the limitations of the current work are discussed and propositions for future research on the networks, cooperation and innovation are identified.33129Adner, R., Helfat, C.E., Corporate Effects and Dynamic Managerial Capabilities (2003) Strategic Management Journal, 24 (10), pp. 1001-1025Balestrin, A., Verschoore, J., Reynes Jr., E., O campo de Estudo sobre Redes de Cooperação Interorganizacional no Brasil" (2010) Revista de Administração Contemporâne, 14 (3), pp. 458-477Bardin, L., (1994) Análise de conteúdo, , Lisboa: Edições SetentaBarney, J., (1996) Gaining and sustaining competitive advantage, , Reading - MA: Adisson WesleyBritto, J., Stallivieri, F., Inovação, cooperação e aprendizado no setor de software no Brasil: análise exploratória baseada no conceito de Arranjos ProdutivosLocais (APLs)" (2010) Economia e Sociedade, 19 (2), pp. 315-358Bullen, X.X.X., Onyx, J., (1998) Measuring social capital in five communities in NSW, p. 2003. , http://www.mapl.com.au/A2.htm, Disponível em. Acesso em: 18 dezCapalo, G., Iandoli, L., Raffa, M., Zollo, G., The Evaluation of Innovation Capabilities in Small Software Firms: A Methodological Approach (2003) Small Business Economics, 21, pp. 343-354Casarotto, F.N., Pires, L.H., (1998) Redes de pequenas e médias empresas e desenvolvimento local, , São Paulo: Atlas(2001) Inovación y tecnología, , Cotec Ideas Básicas. Fundación COTEC. MadridCreswell, J.W., (1998) Qualitative inquiry and research design, , choosing among five traditions. Thousand Oaks: Sage PublicationsDuarte, R., Cooperação Internacional para o Desenvolvimento em Ciência e Tecnologia: A participação Brasileira na Organização Européia paraPesquisa Nuclear (CERN)" (2008) Journal of technology management & innovation, 3 (4), pp. 133-151Freitas, H.M.R., Janissek, R., (2000) Análise léxica e análise de conteúdo, , técnicas complementares, seqüenciais e recorrentes para exploração de dados qualitativos. Porto Alegre: Sagra LuzzattoFukuyama, F., (1996) Confiança: as virtudes sociais e a criação da prosperidade, , Rio de Janeiro: RoccoFukuyama, F., (1999) Social capital and civil society, p. 2003. , http://fdc.org.au/files/pk-sc-cs.pdf, Trabalho apresentado na IMF Conference on Second Generation of Reforms. Disponível em Acesso em: 10 setGrandori, A., Soda, G., Inter-firm Network: antecedents, mechanisms and forms (1995) Organization Studies, 16, p. 2Hackett, S.M., Dilts, D.M., A Real Options-Driven Theory of Business Incubation" (2004) Journal of Technology Transfer, Netherland, 29 (1), pp. 41-54Hayashi Jr, Bulgacov, S., Baraniuk, J.A., Alianças estratégicas em pequenas empresas de massas alimentícias (2003) Colloquium Humanarum, 1, pp. 19-23Kay, J., (1996) Fundamentos do sucesso empresarial, , Rio de Janeiro: CampusLa Rovere, R.L., Hasenclever, L., (2002) Inovação competitividade e adoção de tecnologias da informação e comunicação em pequenas e médias empresas, , Alguns estudos de caso sobre Brasil. Instituto de Economia UFRJ, Rio de JaneiroLaville, C., Dionne, J., (1999) A construção do saber, , Belo Horizonte: UFMGLorange, Roos, J., (1996) Alianças estratégicas, , formação, implementação e evolução. São Paulo: AtlasLübeck, R.M., (2011) "Coopetição: os fatores competitivos aplicados a redes de empresas de transporte público", p. 2011. , V Encontro de Estudos em Estratégia. Porto Alegre, 15 a 17 de Maio deMayer, R.C., (2011) Inovação pela Cooperação Internacional, p. 2011. , http://www.hsm.com.br/editorias/digital/inovacao-pela-cooperacao-internacional, HSM. Disponível em Acesso em: 16 julMelo, A., (2007) Palestra fórum NIITEC, , Porto Alegre, abrilMoraes, C.A., Souza, S.S., Costa, A.C.F., Consentino, H.M., Configuração e cultura organizacional, cooperação e inovação: análise de um modelo de equações estruturais em empresas fabricantes deequipamentos médicos" (2011) Revista Eletrônica de Ciência Administrativa, 10, p. 1Morin, E., (1977) O método I - A natureza da natureza, , Portugal, Publicações Europa-América(1996) Oslo Manual: The Measurement of Scientific and Technological Activities, , European Commission. OECD, Organization for Economic Co-operation and DevelopmentPaula, L.H., (2007) Palestra sobre RedeMAC materiais de construção, , Porto Alegre, MaioPereira, A.S., Lopes, F.D., (2011) "A influência da cooperação estratégica no processo de desenvolvimento do turismo de Natal/RN, , Análise de relações entre os Stakeholders". V Encontro de Estudos em Estratégia. Porto Alegre, 15 a 17 de MaioPrahalad, C.K., A nova era de competição e os líderes emergentes (2000) Imes, 17 (49). , maio/agoPutnam, R.D., Comunidade e democracia: a experiência da Itália moderna, , 2a ed. Rio de Janeiro: FGVSchulze, W.S., (1994) The two schools of thought in resource-based theory. Advances in strategic management, , Shrivastava, PHuff, A. S.Dutton, J. Eresource-based view of the firm (v. 10).Greenwich: Jai PressSchumpeter, J., Teoria do desenvolvimento econômico (1988) uma investigação sobre lucros, capital, juro e ciclo econômico, , Coleção Os Economistas. 3. ed. São Paulo: Nova CulturaSnow, C.C., Miles, R.E., (1983) The role of strategy in the development of a general theory of organizations, , LAMB, R. Advances in Strategic Management. Greenwich: Jay Press, 2Steglich, L., (2007) Palestra no fórum NIITEC, , Porto Alegre, maioTálamo, J.R., Carvalho, M.M.C., Redes de cooperação com foco em inovação: um estudo exploratório (2010) Gestão da Produção, 17 (4), pp. 747-760Teece, D.J., Pisano, G., Shuen, A Dynamic Capabilities and Strategic Management (1988) Strategic Management Journal, 18 (7), pp. 509-533Tidd, J., (2005) Managing innovation, , integrating technological, marketing and organizational changes. Hoboken: WileyVerschoore, J., Balestrin, A., A associação em rede de cooperação influencia os resultados de pequenas e médias empresas?" (2010) Ciências Sociais Unisino, 46 (1), pp. 105-115Wegner, D., Pádula, A.D., (2011) "Explorando a Natureza Transitória da Governança de Redes Interorganizacionais, , Uma Análise Empírica com Redes Horizontais de Empresas". V Encontro de Estudos em Estratégia. Porto Alegre, 15 a 17 de MaioWernerfelt, B., A resource-based view of the firm (1984) Strategic Management Journal, 5, pp. 171-180Winter, S.G., Understanding Dynamic Capabilities (2003) Strategic Management Journal, 24 (10), pp. 991-995Xeyla, R., (2009) Inovação e Cooperação contribuem para o crescimento local e regional, , http://www.rts.org.br/noticias/destaque-2/inovacao-e-cooperacao-contribuem-para-o-crescimento-local-e-regional, Agência Sebrae. Disponível em Acesso em 16 jul 2011Yin, R.K., (2001) Estudo de caso: planejamento e métodos, , 2. ed. Porto Alegre: BookmanZajac, E.J., Commentary on 'Alliances and Networks' (1998) Strategic Management Journal, 19, pp. 319-321. , by R. Gulat